10th November 2023: : Yatharth Hospital and Trauma Care Services Ltd, one of the leading private super specialty hospitals in Delhi NCR, announced its financial results for the quarter ended Sep 30, 2023.

Financial Snapshot

Particulars (Rs mn)Q2 FY24Q2 FY23Change YoYQ1 FY24Change QoQH1 FY24H1 FY23Change YoY
Revenue from Operations1,7131,27934%1,54511%3,2582,39036%
EBITDA Margin26.6%26.2%40bps26.8%(20bps)26.7%24.8%192bps
Profit after Tax (PAT)27616270%19045%46627271%
PAT Margin16.1%12.7%345bps12.3%380bps14.3%11.4%293bps

Key Highlights for Q2 FY2024

  • Operating Revenue is Rs. 1,713 mn, up 34% YoY and 11% QoQ
  • Bed occupancy is 57%, compared to 45% in Q2FY23 and 50% in Q1FY24
  • ARPOB is Rs. 27,561, up 5% YoY
  • EBITDA is Rs. 456 mn, up 36% YoY and 10% QoQ; EBITDA margin expanded by 40 bps YoY to 26.6%
  • PAT is Rs. 276 mn, up 70% YoY and 45% QoQ; PAT margin expanded by 345 bps YoY to 16.1%
  • Earnings per share stood at Rs. 3.80 during the quarter

Key Highlights for H1 FY2024

  • Operating Revenue is Rs. 3,258 mn, up 36% YoY
  • Bed occupancy is 54%, compared to 42% in H1FY23
  • ARPOB is Rs. 27,833, up 6% YoY
  • EBITDA is Rs. 870 mn, up 47% YoY; EBITDA margin expanded by 192 bps YoY to 26.7%
  • PAT is Rs. 466 mn, up 71% YoY; PAT margin expanded by 293 bps YoY to 14.3%
  • Earnings per share stood at Rs. 6.42 during this period
  • Company turns net debt free; Net Cash as on September 30, 2023 is Rs. 3,109 mn
  • RoCE is 25%, while RoE is 19% during this period

Commenting on the performance, Mr. Yatharth Tyagi, Whole Time Director, Yatharth Hospitals said: We are delighted to announce another exceptional quarter of performance. Our revenue has experienced a remarkable 34% year-over-year growth, reaching Rs. 1,713 million, while our Profit After Tax (PAT) has surged by an impressive 70% compared to the same period last year. We are happy to announce that we have turned net debt-free during the quarter. Our ongoing commitment revolves around diversifying our range of medical specialties and introducing new ones across all our hospitals. We are well on track to offer robotic surgeries by the coming quarter and a comprehensive suite of oncology treatments by the fourth quarter of this fiscal year. We are also expanding our organ transplant and growing our medical tourism business, which is projected to drive substantial growth and contribute to an improvement in Average Revenue Per Occupied Bed (ARPOB) in the upcoming quarters.